Literature DB >> 26371168

Healthy older humans exhibit augmented carotid-cardiac baroreflex sensitivity with aspirin during muscle mechanoreflex and metaboreflex activation.

Rachel C Drew1, Cheryl A Blaha2, Michael D Herr2, Sean D Stocker3, Lawrence I Sinoway2.   

Abstract

Low-dose aspirin inhibits thromboxane production and augments the sensitivity of carotid baroreflex (CBR) control of heart rate (HR) during concurrent muscle mechanoreflex and metaboreflex activation in healthy young humans. However, it is unknown how aging affects this response. Therefore, the effect of low-dose aspirin on carotid-cardiac baroreflex sensitivity during muscle mechanoreflex with and without metaboreflex activation in healthy older humans was examined. Twelve older subjects (6 men and 6 women, mean age: 62 ± 1 yr) performed two trials during two visits preceded by 7 days of low-dose aspirin (81 mg) or placebo. One trial involved 3 min of passive calf stretch (mechanoreflex) during 7.5 min of limb circulatory occlusion (CO). In another trial, CO was preceded by 1.5 min of 70% maximal voluntary contraction isometric calf exercise (mechanoreflex and metaboreflex). HR (ECG) and mean arterial blood pressure (MAP; Finometer) were recorded. CBR function was assessed using rapid neck pressure application (+40 to -80 mmHg). Aspirin significantly decreased baseline thromboxane B2 production by 83 ± 4% (P < 0.05) but did not affect 6-keto-PGF1α. After aspirin, CBR-HR maximal gain and operating point gain were significantly higher during stretch with metabolite accumulation compared with placebo (maximal gain: -0.23 ± 0.03 vs. -0.14 ± 0.02 and operating point gain: -0.11 ± 0.03 vs. -0.04 ± 0.01 beats·min(-1)·mmHg(-1) for aspirin and placebo, respectively, P < 0.05). In conclusion, these findings suggest that low-dose aspirin augments CBR-HR sensitivity during concurrent muscle mechanoreflex and metaboreflex activation in healthy older humans. This increased sensitivity appears linked to reduced thromboxane sensitization of muscle mechanoreceptors, which consequently improves CBR-HR control.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  age; aspirin; baroreflex; mechanoreflex; thromboxane

Mesh:

Substances:

Year:  2015        PMID: 26371168      PMCID: PMC4631535          DOI: 10.1152/ajpheart.00444.2015

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  42 in total

Review 1.  Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

Authors:  C Patrono; B Coller; J E Dalen; G A FitzGerald; V Fuster; M Gent; J Hirsh; G Roth
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Cardiac vagal and sympathetic efferent discharges are differentially modified by stretch of skeletal muscle.

Authors:  J Murata; K Matsukawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-01       Impact factor: 4.733

Review 3.  Neural circuits controlling cardiorespiratory responses: baroreceptor and somatic afferents in the nucleus tractus solitarius.

Authors:  Jeffrey T Potts
Journal:  Clin Exp Pharmacol Physiol       Date:  2002 Jan-Feb       Impact factor: 2.557

4.  Effects of aging on cardiovascular responses to parasympathetic withdrawal.

Authors:  John R Stratton; Wayne C Levy; James H Caldwell; Arnold Jacobson; Janet May; Dale Matsuoka; Ken Madden
Journal:  J Am Coll Cardiol       Date:  2003-06-04       Impact factor: 24.094

5.  Spontaneous baroreflex sensitivity in young and older people during voluntary and electrically evoked isometric exercise.

Authors:  Charlotte A Carrington; Michael J White
Journal:  Age Ageing       Date:  2002-09       Impact factor: 10.668

6.  Effect of ischemia on responses of group III and IV afferents to contraction.

Authors:  M P Kaufman; K J Rybicki; T G Waldrop; G A Ordway
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-09

7.  Effects of static muscular contraction on impulse activity of groups III and IV afferents in cats.

Authors:  M P Kaufman; J C Longhurst; K J Rybicki; J H Wallach; J H Mitchell
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-07

8.  Heart rate at the onset of muscle contraction and during passive muscle stretch in humans: a role for mechanoreceptors.

Authors:  V F Gladwell; J H Coote
Journal:  J Physiol       Date:  2002-05-01       Impact factor: 5.182

Review 9.  How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life.

Authors:  G Parati; M Di Rienzo; G Mancia
Journal:  J Hypertens       Date:  2000-01       Impact factor: 4.844

10.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

View more
  4 in total

1.  Investigation of the mechanisms of cyclooxygenase-mediated mechanoreflex sensitization in a rat model of simulated peripheral artery disease.

Authors:  Alec L E Butenas; Tyler D Hopkins; Korynne S Rollins; Kennedy P Felice; Steven W Copp
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-30       Impact factor: 4.733

2.  Muscle mechanoreflex activation via passive calf stretch causes renal vasoconstriction in healthy humans.

Authors:  Rachel C Drew; Cheryl A Blaha; Michael D Herr; Ruda Cui; Lawrence I Sinoway
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-04-05       Impact factor: 3.619

3.  Cyclooxygenase inhibition does not impact the pressor response during static or dynamic mechanoreflex activation in healthy decerebrate rats.

Authors:  Korynne S Rollins; Tyler D Hopkins; Alec L Butenas; Kennedy P Felice; Carl J Ade; Steven W Copp
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-06-26       Impact factor: 3.619

Review 4.  Baroreflex and neurovascular responses to skeletal muscle mechanoreflex activation in humans: an exercise in integrative physiology.

Authors:  Rachel C Drew
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-08-30       Impact factor: 3.619

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.